Abstract: The present invention addresses the problem of providing a new compound that binds specifically to intracellular and/or extracellular vesicles, a cellular vesicle stain, and a method for fluorescent staining of cellular vesicles. The problem can be solved by a compound represented by formula (1). (In formula (1), R1 represents H, a C1-C6 alkyl group, a hydroxy group, an amino group, or a carboxy group. R2 represents H, a C1-C18 alkyl group, a C1-C18 alkoxy group, a halogen element, NO2, or N(CH3)2. R3 and R4 each independently represent H or CH3. However, R3 and R4 may bond to each other to form a ring, in which case R3 and R4 are CH2. 1 represents 1 or 2; m represents 0 or 1; and n represents 1, 2, or 3. Z represents a fluorescent group.

Abstract: An object of the present invention is to provide a therapeutic preparation and method for diseases associated with cartilage loss, cartilage degeneration and/or cartilage thinning. The present invention provides a therapeutic preparation comprising a pterosin derivative or a pharmaceutically acceptable salt thereof for diseases associated with cartilage loss, cartilage degeneration and/or cartilage thinning; and a therapeutic method for the diseases.

Abstract: The use of salt-inducible kinase 3 allows screening for a substance having an effect of increasing cartilage volume and/or an effect of normalizing chondrocyte differentiation. A modified chondrocyte in which the expression or function of salt-inducible kinase 3 gene is inhibited or enhanced can be used to ameliorate a disease associated with reduced cartilage volume and/or a disease associated with impaired cartilage growth.

Abstract: An object of the present invention is to provide a therapeutic preparation and method for diseases associated with cartilage loss, cartilage degeneration and/or cartilage thinning. The present invention provides a therapeutic preparation comprising a pterosin derivative or a pharmaceutically acceptable salt thereof for diseases associated with cartilage loss, cartilage degeneration and/or cartilage thinning; and a therapeutic method for the diseases.

Abstract: The use of salt-inducible kinase 3 allows screening for a substance having an effect of increasing cartilage volume and/or an effect of normalizing chondrocyte differentiation. A modified chondrocyte in which the expression or function of salt-inducible kinase 3 gene is inhibited or enhanced can be used to ameliorate a disease associated with reduced cartilage volume and/or a disease associated with impaired cartilage growth.

Abstract: The polypeptide of the present invention has the amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8, 10, or 12. The polypeptide of the present invention is useful as an agent for preventing or improving a disease with which the metabolic disorder of fat cells or the like is associated.